India covid-19 patient India

Bajaj Healthcare launches Covid treatment drug 2-DG under brand name 'DGJAJ'

Reading now: 700
www.livemint.com

2-DG), an antiviral drug used for treating Covid-19 patients, under the brand name ‘DGJAJ’ in collaboration with Defence Research and Development Organisation (DRDO).

The API manufacturer had received a licence from DRDO to manufacture the anti-Covid medication on July 7. The production of DGJAJ began from today onwards, the company said in a regulatory filing on Sunday. “Health experts are anticipating a third wave of Covid-19, which may be even more severe as the virus has undergone several mutations over the time.

We hope the availability of an effective treatment such as 2-Deoxy-D-Glucose (2-DG) will offer patients with much needed and timely therapy option," said Anil Jain, Joint Managing Director of Bajaj Healthcare.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA